Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The progression of ovarian cancer, from cell transformation through invasion of normal tissue, relies on communication between tumor cells and their adjacent stromal microenvironment. Through a natural selection process, an autocrine-paracrine communication loop establishes reciprocal reinforcement of growth and migration signals. Thus, the cancer-activated stromal response is similar to an off-switch-defective form of the normal, universal response needed to survive insult or injury. It is becoming clearer within the cancer literature base that tumor stroma plays a bimodal role in cancer development: it impedes neoplastic growth in normal tissue while encouraging migration and tumor growth in a co-opted desmoplastic response during tumor progression. In this review, we discuss this reciprocal influence that ovarian cancer epithelial cells may have on ovarian stromal cell-reactive phenotype, stromal cell behavior, disrupted signaling networks, and tumor suppressor status in the stroma, within the context of cancer fibroblast studies from alternate cancer tissue settings. We focus on the exchange of secreted factors, in particular interleukin 1β and SDF-1α, between activated fibroblasts and cancer cells as a key area for future investigation and therapeutic development. A better understanding of the bidirectional reliance of early epithelial cancer cells on activated stromal cells could lead to the identification of novel diagnostic stromal markers and targets for therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 2×
“This perspective, which has been pioneered by Dvorak [36], Rowley [18], and others, implies that the cancer-activated reactive stromal response is an off-switch-defective form of the normal, universal biologic response needed to survive tissue insult or injury [35].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814 · cited 2×
“Thus, specific genetic mutations among diverse histomorphologic ovarian cancer subtypes allow pathologists to identify and diagnose tumor specimens by microscopy [7,8].”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Dunne, A., & O'Neill, L. A. J. (2003) · Science's STKE · doi:10.1126/stke.2003.171.re3 · Cited by 711
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605752103 · Cited by 341 · cited 4×
“Furthermore, we have used our Ras-mediated ovarian cancer mouse xenograft model to demonstrate that GRO-α– expressing senescent ovarian fibroblasts significantly promoted xenograft tumorigenesis of preneoplastic ovarian surface epithelial cells [63].”
BackgroundMethodInfluentialSelf-citationp53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336 · cited 2×
“[143] Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ,”
BackgroundMicroenvironmental regulation of cancer development
Hu, M., & Polyak, K. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.006 · Cited by 330 · cited 2×
“[28] Hu M and Polyak K (2008).”
BackgroundSelective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324 · cited 2×
“[146] Hill R, Song Y, Cardiff RD, and Van Dyke T (2005).”
BackgroundKenny, H. A., Krausz, T., Yamada, S. D., & Lengyel, E. (2007) · International Journal of Cancer · doi:10.1002/ijc.22874 · Cited by 243 · cited 2×
“[41] Kenny HA, Krausz T, Yamada SD, and Lengyel E (2007).”
BackgroundZhang, L., Yang, N., Conejo Garcia, J.-R., Mohamed, A., Benencia, F., Rubin, S. C., Allman, D., & Coukos, G. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64505-1 · Cited by 151
Evidence for Nonautonomous Effect of p53 Tumor Suppressor in Carcinogenesis
Kiaris, H., Chatzistamou, I., Trimis, G., Frangou-Plemmenou, M., Pafiti-Kondi, A., & Kalofoutis, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3791 · Cited by 128
Jotzu, C., Alt, E., Welte, G., Li, J., Hennessy, B. T., Devarajan, E., Krishnappa, S., Pinilla, S., Droll, L., & Song, Y.-H. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/695162 · Cited by 114
Greenaway, J., Moorehead, R., Shaw, P., & Petrik, J. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.035 · Cited by 100 · cited 2×
“[162] Greenaway J, Moorehead R, Shaw P, and Petrik J (2008).”
Background
Cited by
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0893 · Cited by 689
Self-citationInflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
Self-citationMicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295
Metadata
- Authors
- Schauer, I. G., Sood, A. K., Mok, S., & Liu, J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 13
- Issue
- 5
- Pages
- 393-405
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W1907104379
- Cited by
- 155
- References
- 16
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.